Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MM 2018 | A novel mechanism of action for daratumumab in myeloma

The anti-CD38 antibody daratumumab, a success in multiple myeloma (MM), has pleiotropic mechanisms. Here, Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, discusses a novel mechanism of action for daratumumab, trogocytosis. This video was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.